Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Silenseed logo — company profile

Silenseed

Founded 1999 Series A Total: $10.50M Biopharma, Biotechnology +2

General Information

Company Name Silenseed
Founded Year 1999
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Silenseed. To contact Silenseed, visit silenseed.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Silenseed

Silenseed is a clinical stage biopharmaceutical company established in 1999 with a focus on developing proprietary RNA interference (RNAi)-based cancer drugs and advanced delivery systems. The company's innovative drugs, in conjunction with the newly developed delivery system LODER™ (LOcal Drug EluteR), hold significant promise for providing highly effective treatment options for solid tumor cancers. Silenseed's research and development pipeline includes pancreatic cancer, prostate cancer, and certain types of brain cancers. The company recently secured a Series A investment on 01 December 2020 from Laursen van Swieten. Silenseed operates within the industries of Biopharma, Biotechnology, and Health Care.

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed 1
Laursen van Swieten
Laursen van Swieten
01 Dec 2020
Venture Round $10.00M -
01 Aug 2017
Venture Round $500.00K -
08 Apr 2014

Silenseed Alternatives & Competitors

View All Alternatives
Silenseed vs
SpringWorks Therapeutics
SpringWorks Therapeutics United States

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach t...

Post-IPO Equity
372 employees
Biopharma, Biotechnology
Silenseed vs
Novocure
Novocure Switzerland

Patient-forward: Aspiring to make a difference in cancer

Post-IPO Debt
1384 employees
Biotechnology, Health Care
Silenseed vs
Cavion
Cavion

Empowering therapies for cancer and neurologic diseases through pioneering ion channel inhibition

Series A
Biotechnology, Health Care
View all alternatives

FAQ About Silenseed

Silenseed is a clinical stage biopharmaceutical company focused on developing proprietary RNA interference (RNAi)-based cancer drugs and advanced delivery systems with the aim of effectively treating malignant solid tumors. The company's innovative drugs, combined with the newly developed delivery...
Silenseed was founded in 1999.
Silenseed operates in Biopharma, Biotechnology, Health Care and Health and Wellness.
Silenseed has completed 3 funding rounds, raising a total of $10.50M. The latest funding stage is Series A.
Top alternatives and competitors to Silenseed include SpringWorks Therapeutics, Novocure, Cavion, Tarveda Therapeutics, BBB Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Silenseed and SpringWorks Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Silenseed, https://bouncewatch.com/company/silenseed, updated 25 July 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes